(z)-2-[(3-carbamoyl-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)amino]-4-(4-r-phenyl)-4-oxobut-2-enoic acids, having analgesic activity

FIELD: chemistry.

SUBSTANCE: invention relates to organic chemistry and specifically to biologically active substances which are (Z)-2-[(3-carbamoyl-4,5,6,7-tetrahydrobenzo [b]thien-2-yl)amino]-4-(4-R-phenyl)-4-oxobut-2-enoic acids of general formula (1-3) . The acids (1-3) are obtained by reacting 4-(4-R-phenyl)-2,4-dioxobutanoic acid with an amide of 2-amino-4,5,6,7-tetrahydro[b]thiophene-3-carboxylic acid in a medium of ethyl alcohol at 60°C, followed by extraction of the end product using existing methods.

EFFECT: obtaining novel compounds with high output, having marked analgesic activity and low toxicity.

1 tbl, 4 ex

 

The invention relates to the field of organic chemistry, new biologically active substances of class 2-amino-4-aryl-4-dioxobutane acids, namely (Z)-2-[(3-carbarnoyl-4,5,6,7-tetrahydrobenzo[b]Tien-2-yl)amino]-4-(4-R-phenyl)-4-exabot-2-anawim acids (1-3), the General formula

possessing analgesic activity, suggesting their use in medicine as a drug with analgesic properties.

Similar in structure to the claimed compounds is 4-(4-were)-4-oxo-2-[3-etoxycarbonyl-4,5-dimethylthiophene-2-ylamino]but-2-ANOVA acid (4), which has anti-inflammatory and analgesic activity [U.S. Pat. 2389724 Grew. Federation. No. 2008151813/04; Appl. 25.12.08; publ. 20.05.10, bull. No. 14] formula:

The data on analgesic activity:

ConnectionThe latent period of the defensive reflex, after 2 hours
423,5

A benchmark comparison of selected ortofen formula

which is widely used in medical practice and is an aliphatic amino acid and similar in action [Mashkovsky PPM Lech is only means. - 15-ed., Rev., Corr. and extra - M.: OOO "New wave", 2005. - S].

Object of the invention is the finding in a series of derivatives of 2-amino-4-aryl-4-dioxobutane acid substances with pronounced analgesic effect and low toxicity.

This object is achieved by obtaining (Z)-2-[(3-carbarnoyl-4,5,6,7-tetrahydrobenzo[b]Tien-2-yl)amino]-4-(4-R-phenyl)-4-exabot-2-novyh acids, which possess analgesic activity.

The claimed compounds (1-3) are synthesized by the interaction of 4-(4-R-phenyl)-2,4-dioxaborinane acid with Amida 2-amino-4,5,6,7-tetrahydro[b]thiophene-3-carboxylic acid in the environment of ethanol at 60°C, followed by separation of the target product with known methods using the pattern

Example 1. Obtain (Z)-2-[(3-carbarnoyl-4,5,6,7-tetrahydrobenzo[b]Tien-2-yl)amino]-4-phenyl-4-exabot-2-ene acid (1). To a solution of 1.92 g (0.01 mol) of 4-phenyl-2,4-dioxaborinane acid in 20 ml of ethyl alcohol was added a solution of 1.96 g (0.01 mol) of the amide of 2-amino-4,5,6,7-tetrahydro[b]thiophene-3-carboxylic acid in 20 ml of the same solvent and incubated at room temperature for 24 hours. The mixture is cooled to 0°C, the precipitation is filtered off and recrystallized from acetonitrile. Yield 3.35 g (90.48%). TPL 166-167°C. Found, %: C 61.60; H 4.93; N, 7.58; 17.29; S 8.64 C19H18N2O4S. Calculated, %: C 61.61; N, 4.90; N, 7.56; 17.28; S 8.66. IR is the range (operation 1202, vaseline oil, ν, cm-1): 3400 (NH2, 3184 (ush. NH), 1706 (COO), 1567. An NMR spectrum1N (Varian Mercury 300 (300 MHz), DMSO-d6, GMDS, δ, ppm): to 1.79 (m, 4H, (CH2)4), to 2.66 (m, 4H, (CH2)4), 6,41 (s, 1H, C=CH), 7,47 (ush. s, 2H, NH2), to 7.59-with 8.05 (m, 5H, arene.), of 12.33 (s, 1H, NH).

The compound obtained 1 represents a bright red crystalline substance, soluble in chloroform, toluene, acetone, insoluble in water and hexane.

Example 2. Obtain (Z)-2-[(3-carbarnoyl-4,5,6,7-tetrahydrobenzo[b]Tien-2-yl)amino]-4-(4-chlorophenyl)-4-exabot-2-ene acid (2). Yield 3.67 g (90,64%). TPL 183-184°C. Found, %: 56.37; N, 4.22; N, 6.91; 15.84; S 7.90; Cl 8.75 C19H17ClN2O4S. Calculated, %: 56.37; N, 4.23; N, 6.92; 15.81; S 7.92; Cl 8.76. IR spectrum (operation 1202, vaseline oil, ν, cm-1): 3390 (NH2), 3186 (ush. NH), 1709 (COO), 1577. An NMR spectrum1N (Varian Mercury 300 (300 MHz), DMSO-d6, GMDS, δ, ppm): 1,78 (m, 4H, (CH2)4), to 2.66 (m, 4H, (CH2)4), 6,44 (s, 1H, C=CH), 7,46 (ush. s, 2H, NH2), EUR 7.57 (d, J 7.5, 2H, arene.), 8,01 (d, J 7.5, 2H, arene.), 12,31 (s, 1H, NH).

The obtained compound 2 is a bright red crystalline substance, soluble in chloroform, toluene, acetone, insoluble in water and hexane.

Example 3. Obtain (Z)-2-[(3-carbarnoyl-4,5,6,7-tetrahydrobenzo[b]Tien-2-yl)amino]-4-(4-were)-4-exabot-2-ene acid (3). Yield 3.09 g (80,47%). TPL 150-151°C. Found, %: C 62.45; N, 5.25; N, 7.31; at 16.65; S 8.3 C 20H20N2O4S. Calculated, %: C 62.48; N, 5.24; N, 7.29; at 16.65; S, 8.34. IR spectrum (operation 1202, vaseline oil, ν, cm-1): 3343 (NH2), 3131 (ush. NH), 1708 (COO), 1574. An NMR spectrum1N (Varian Mercury 300 (300 MHz), DCCl3, GMDS, δ, ppm): 1.57 in (m, 4H, (CH2)4), at 1.91 (m, 2H, (CH2)4), a 2.45 (s, 3H, Me), and 2.79 (m, 2H, (CH2)4), of 5.89 (ush. s, 2H, NH2), to 7.09 (s, 1H, C=CH), 7,33 (d, J 8.1, 2H, arene.), 7,94 (d, J 8.1, 2H, arene.), 12,65 (s, 1H, NH).

The compound obtained 3 is a bright red crystalline substance, soluble in chloroform, toluene, acetone, insoluble in water and hexane.

Example 4. Biological activity of compounds (1-3). Acute toxicity (LD50(mg/ml) of the compound (1-3) was determined by the method Hendersen [Pershin GN. Methods of experimental chemotherapy. M, P.100, 109-117 (1971)]. Compounds (1-3) were injected intraperitoneally white mice weighing 16-18 g in the form of a suspension in 2% starch mucus and observed the behavior and the death of the animal within 10 days. For the studied compounds (1-3) LD50is > 1500 mg/kg

According to the classification of the toxicity of preparations of compound (1-3) refer to the V class is practically non-toxic drugs [Izmerov NF, Sanotski I., Sidorov, K.K. Settings toxicometric industrial poisons acute exposure: a Handbook. M., 1977. - S].

Analgesic activity of the compounds (1-3) were studied on the devil is orodnik mice (females) weighing 18-22 g with test "hot plate" [Radell Z.O., Selitto J.J. A method for measurement of analgesic activity on inflamed tissue // Arch. Intermat. Pharmacodun. Et ther. 1957. - Vol.11. No. 4 - S.409-419].

The investigated compounds were administered intraperitoneally in the form of 2% starch mucilage in the dose of 50 mg/kg for 0.5 h before the animals on the premises heated to 53.5°C metal plate. Measure of pain sensitivity was the duration of stay of the animal on the hot plate until the licking of the hind paws, measured in seconds. The effect was compared with ortofen.

The test results presented in the table.

Table
Analgesic activity and acute toxicity of compounds (1-3)
ConnectionDose, mg/kgLD50mg/kgThe latent period of the defensive reflex,
1.5 hours
Control10,0
Ortofen10 [U50]7426,2
150 >150022,6
250>150026,0
350>150024,4

As can be seen from the table, the claimed compounds (1-3) show a pronounced analgesic activity and less toxic than the product comparison - ortofen. Therefore, the claimed compounds (1-3) may find application in medical practice as analgesic drugs.

(Z)-2-[(3-carbarnoyl-4,5,6,7-tetrahydrobenzo[b]Tien-2-yl)amino]-4-(4-R-phenyl)-4-exabot-2-ENOVIA acid (1-3) General formula:

possessing analgesic activity.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to N-R- amides of (Z)-2-[(3-(ethoxycarbonyl)-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)amino]-4-phenyl-4-oxobut-2-enoic acids (1-4) of general formula:

.

Acid amides (1-4) are obtained by reacting ethyl ether of 2-[(2-oxo-5-phenyl-(2H)-furanylidene)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid with R-amines in a medium of pure toluene at 25-110°C, followed by separation of the end product using known techniques.

EFFECT: obtaining novel compounds with high output, having marked analgesic activity and low toxicity.

2 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to compounds of formula 1a:

, wherein: A means CH=CH orS; R23 means hydrogen, halogen, (C1-C4)-alkyl, (C1-C4)-alkyloxy or (C1-C4)-alkyl-S-; R24 means hydrogen or halogen when A means CH=CH or hydrogen, halogen, (C1-C4)-alkyl when A means S; X means N(H)C=O, N(H)S(O)2, C=ON(H) or S(O)2N(H); Y means C(R12)=C(R13), N=C(R14) or C(R15)=N, or condensed optionally substituted 5-7-member carbocyclyl; R12 means hydrogen, halogen, (C1-C10)-alkyl, (C2-C10)-alkenyl, (C3-C6)-cycloalkyloxy, (C3-C10)-cycloalkenyloxy, (C3-C6)-cycloalkyl, (C3-C10)-cycloalkenyl, (C3-C6)-cycloalkyl[(C1-C4)-alkyl or (C2-C4)-alkenyl], (C3-C6)-cycloalkyl (C1-C4)-alkyloxy, (C1-C10)-alkyloxy, (C3-C10)-alkenyloxy, (C1-C10)-alkyl-S-, cyano, (C1-C10)-alkylcarbonyl- or phenyl; R13 means hydrogen, halogen or (C1)-alkyl; R14 means hydrogen or (C1-C3)-alkyl-S(O)m; R15 means hydrogen, halogen, (C1-C10)-alkyl, amino, [(C1-C10)-alkyl or (C2-C10)-alkenyl] amino, [(C1-C10)-alkyl or (C2-C10)-alkenyl]((C1-C10)-alkyl)amino or nitro; R21 means hydrogen; R22 means hydrogen, halogen, (C1)-alkyl, while Y means C(R12)=C(R13), N=C(R14) or C(R15)=N; R51 means COOH or CONH(R53); R53 means R55-SO2- or tetrazolyl; R55 means (C1-C4)-alkly; and m is equal to 0; wherein all specified phenyl groups may be independently substituted by one or more halogen atoms; wherein all specified alkyl groups may be independently substituted by one or more fluorine atoms; or its stereoisomer form, a mixture of stereoisomer forms in any ratio or its physiologically acceptable salt, provided the following compounds are excluded: 2-benzoylamino-2,3-dihydro-2-indencarboxylic acid; 2-(naphthalin-2-ylsulphonylamino)indane-2-carboxylic acid. Also, the invention refers to a pharmaceutical composition possessing CXCR5 receptor inhibitory activity on the basis of the compounds described above, as well as a method of treating a patient, involving introducing said compounds into the patient.

EFFECT: there are prepared and described the new compounds which possess CXCR5 inhibitory action and may be used for treating and preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, and Crohn's disease.

17 cl, 397 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel substituted cyclohexylmethyl derivatives, having serotonin, noradrenaline or opioid receptor inhibiting activity, optionally in form of cis- or trans-diastereomers or mixture thereof in form of bases or salts with physiologically compatible acids. In formula (1): R2 denotes H or OH; R1 and R2 together denote or =N-OH, R3 denotes a phenyl residue which is unsubstituted or monosubstituted with a halogen atom or a heteroaryl residue selected from a five-member sulphur-containing heteroaryl such as a thienyl residue or an unsubstituted phenyl residue bonded through a C1-C4alkyl group, R4 and R5 independently denote an unsubstituted C1-C3alkyl or R4 and R5 together denote (CH2)3-6, R8 denotes a linear saturated C1-C4 alkyl group bonded with an aryl, which is unsubstituted or monosubstituted with halogen atoms, R9 denotes a saturated C1-C8alkyl; values of radicals R1, m, n, R6, R7, R10-R13 are given in the claim. The invention also relates to methods of producing compounds of formula (I), a medicinal agent containing said compounds, use of compounds of formula (I) to prepare a medicinal agent for anaesthetic treatment during sharp, neuropathic or chronic pain and for treating depression, urinary incontinence, diarrhoea and alcoholism.

EFFECT: high efficiency of using the compounds.

32 cl, 501 ex, 21 tbl

FIELD: organic chemistry, chemical technology.

SUBSTANCE: invention relates to a method for preparing benzo[b]thiophenes of the formula (I):

wherein X represents sulfur atom (S); R1 represents CN or COOA; each among R2 and R3 represents hydrogen atom; A represents (C1-C6)-alkyl. Method involves the dehydrogenation reaction of tetrahydrobenzothiophene of the formula (II):

wherein R1-R3 and X have values given above; Ac represents (C1-C6)-acyl in the presence of a catalyst taken in the catalytic amount based on precious metal and hydrogen acceptor followed by deacylation reaction of acylated amino-group by amine effect. Compounds of the formula (I) are intermediate substances in producing dyes, agents for plants protection and in manufacture of drugs.

EFFECT: improved preparing method.

7 cl, 3 ex

The invention relates to derivatives of benzo[b]thiophene acid of the formula I, the method of production thereof, which are useful as starting materials to obtain drugs, and to a method for producing derivatives of 5-hydroxybenzo[b] thiophene-3-carboxylic acid of formula VI, which are specific antagonists PGD2using the above derivatives of the formula I

The invention relates to a method for producing derivatives benzothiophenes formula I, including the interaction of amerosport formula (II) or its salt with the compound of the formula (III) or its reactive derivative, the oxidation of the resulting product in the presence of 2,2,6,6-tetramethylpiperidine-1-oxide and then liaising with ridom in the conditions of a Wittig reaction with subsequent optional unprotect

The invention relates to Amida aminodiphenylamine acid I in which R1, R2each independently of one another denotes N, And, moreover, one of the residues R1or R2in all cases has a value other than H; R1and R2together represent alkylene with 3-5 C-atoms, R3and R4each independently of one another denotes N or C1-C4-alkoxy; R3and R4together denote also-O-CH2-O - or-O-CH2-CH2-O-; And denotes alkyl with 1-6 C-atoms, R5means-X-Y, X represents CO, Y represents a phenyl or cyclohexyl, unsubstituted monosubstituted COOH or cooa, n denotes 1, 2 or 3, as well as their physiologically acceptable salts

The invention relates to benzodioxepine derivative, intermediate compounds for them, containing them, pharmaceutical compositions containing them antagonists PGD2(prostaglandin D2and containing medicines for the treatment of nasal obstruction

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and chemical-pharmaceutical industry, namely to drug preparations used in various spastic intestinal and pancreatic-biliary conditions, especially in irritable bowel syndrome, and to methods for making them. The drug preparation in the form of an orally dispersible tablet characterised by the fact that it contains a combination of hyoscine butyl bromide and diclofenac or its sodium salt in complex with polacrilin potassium in ratio of diclofenac or its sodium salt and polacrilin potassium of 1:2, and pharmaceutically acceptable additives containing mannitol, aspartame and crospovidone. Polyvinyl pyrrolidone K30, a flavouring agent and anhydrous colloidal silicon dioxide.

EFFECT: tablets have the improved bioavailability of the agent.

2 cl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of the class of spiro[pyrrole-2,5'-pyrrolo[2,3-d]pyrimidine, particularly 1,6'-diaryl-3-aroyl-4-hydroxy-1',3'-dimethylspiro[pyrrole-2,5'-pyrrolo[2,3-d]pyrimidine]-2',4',5'(1H,1H',3'H)-triones, having a structural formula given below, as well as a method for production thereof. In the structural formula of compounds disclosed herein, , Ar1=Ph, C6H4Me-4; Ar2=Ph, C6H4Me-4, C6H4OMe-4, C6H4Br-4. The method of producing the compounds involves reacting 1-aryl-4,5-diaroyl-1H-pyrrole-2,3-diones with 6-amino-1,3-dimethylpyrimidine-2,4(1H,3H)-dione in a medium of an inert aprotic solvent. The process is normally carried out at temperature of 82-84°C, using pure dichloroethane as the solvent.

EFFECT: compounds have analgesic activity and can be used in pharmacology as potential medicaments, as well as primary products for synthesis of novel heterocyclic systems.

4 cl, 1 tbl, 2 dwg, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds derived from taurine having formula , wherein R is selected from 2-(6-methoxy-2-naphthyl)propionic acid, [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid and salts thereof. The invention also relates to a method of producing compounds of formula (I) by reacting taurine with a compound belonging to a group of non-steroid anti-inflammatory preparations comprising 2-(6-methoxy-2-naphthyl)propionic acid, [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid, in the presence of a catalyst in a corresponding organic medium, and anti-inflammatory pharmaceutical compositions containing at least one compound of formula I, having non-steroid anti-inflammatory activity.

EFFECT: improved characteristics of compounds.

8 cl, 4 tbl, 10 dwg, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a pharmaceutical composition with anti-inflammatory, cardio- and chondroprotective activity, action preventing gastropathies caused by non-steroidal anti-inflammatory drugs. The above composition contains sodium diclofenac 5 - 25%, quercetin in the form of dihydrate or an anhydrous substance 10 - 40%, polyvinylpyrrolidone 10 - 50%, sodium lauryl sulphate 0.25 - 10%, microcrystalline cellulose 20 - 40%, croscarmellose sodium salt 1 - 15% and magnesium stearate 0.25 -5.0% at total weight of the composition. The invention also concerns the method for preparing the specified compound.

EFFECT: invention provides preparing the pharmaceutical composition with high anti-inflammatory, cardio- and chondroprotective activities.

2 cl, 2 dwg, 17 tbl, 16 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel 1,3-dihydroimidazole-2-thione derivatives of formula I: , in which R1, R2 and R3, identical or different, denote hydrogen or halogen; R4 denotes alkyl aryl; X denotes an oxygen atom; n equals 2 or 3; individual (R)-enantiomers thereof; or pharmaceutically acceptable salts thereof, where the term "alkyl" denotes straight or branched hydrocarbon chains which contain one to six carbon atoms; the term "aryl" denotes a phenyl or naphthyl group; the term "halogen" denotes fluorine, chlorine, bromine or iodine. The invention also relates to a method of producing said compounds, a pharmaceutical composition based on said compounds, having inhibiting action on dopamine-beta-hydroxylase, methods of treating different cardiovascular diseases such as hypertension and chronic heart failure, and use of compounds of formula 1 to produce drugs for treating said diseases.

EFFECT: improved properties of derivatives.

32 cl, 2 dwg, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to N-R- amides of (Z)-2-[(3-(ethoxycarbonyl)-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)amino]-4-phenyl-4-oxobut-2-enoic acids (1-4) of general formula:

.

Acid amides (1-4) are obtained by reacting ethyl ether of 2-[(2-oxo-5-phenyl-(2H)-furanylidene)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid with R-amines in a medium of pure toluene at 25-110°C, followed by separation of the end product using known techniques.

EFFECT: obtaining novel compounds with high output, having marked analgesic activity and low toxicity.

2 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel pyridin-2-one and pyridazin-3-one derivatives, having Btk inhibiting activity. In formulae I-IV:

,

R denotes -R1-R2-R3 or -R2-R3; R1 denotes a heteroaryl containing 6 ring atoms, including one N heteroatom; R2 denotes -C(=O), -C(=O)N(R2'), where R2' denotes H; R3 denotes R4; where R4 is a lower alkyl, heterocycloalkyl, (lower alkyl) heterocycloalkyl or heterocycloalkyl (lower alkyl), where the heterocycloalkyl contains 6 ring atoms, including two heteroatoms selected from N and O; and where R4 can be substituted with one or more substitutes selected from lower alkyl, oxo group and lower alkoxy group; X denotes CH or N; Y1 denotes lower alkyl; n and m are equal to 0; values of radicals Y2, Y4 are given in the claim.

EFFECT: improved properties of compounds.

6 cl, 2 tbl, 42 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an extract of one or more bacterial strains Lactobacillus. The extract of one or more bacterial strains Lactobacillus representing a soluble extract, wherein the extract contains chemically modified bacterial molecules prepared by the action of an alkaline medium on one or more bacterial strains Lactobacillus; the extract is effective in treating diseases associated with the anti-inflammatory cytokine production imbalance. A method for preparing the extract of one or more bacterial strains Lactobacillus. A pharmaceutical composition effective for reducing at least one symptom associated with at least one condition specified in a respiratory disorder, an allergic condition, an urinary disorder and a gastric disorder, containing the extract. A nutritional composition. A pharmacological composition effective in treating the diseases associated with the anti-inflammatory cytokine production imbalance, containing the extract. A method of relieving the above symptoms. The extract prepared by the above method.

EFFECT: extract is effective in treating the diseases associated with the anti-inflammatory cytokine production imbalance.

21 cl, 7 dwg, 23 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents a combined analgesic and anti-spasmodic drug containing caffeine and drotaverine hydrochloride, characterised by the fact that as active substances it additionally contains ketorolac or a compound thereof, such as ketorolac tromethamine and diphenylhydramine in the amount of: ketorolac or a compound thereof, such as ketorolac tromethamine 5 - 40 mg, caffeine 50 - 100 mg, diphenylhydramine 20 - 50 mg, drotaverine hydrochloride 40 - 80 mg.

EFFECT: invention provides developing the drug possessing strong analgesic action in moderate or severe pain syndromes, various cramping pains.

2 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a composition for treating or preventing an inflammation. What is described is using a primary composition containing a planch suspension in milk or a carrier containing a milk protein, however containing no insoluble fibres for preparing a product for treating or preventing the inflammation.

EFFECT: composition is effective for treating or preventing the inflammation.

14 cl, 13 dwg, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel 4-aminocyclohexane derivatives, having affinity for the µ- opioid receptor and ORL1 receptor. In formula

Y1, Y1', Y2, Y2', Y3, Y3', Y4 and Y4' denote -H; Q denotes -R0, -C(O)-R0 or -C(=NH)-R0; R0 and R3 in each case independently denote -C1-8-aliphatic, -aryl, -heteroaryl, -C1-8-aliphatic-C5-cycloaliphatic, -C1-8-aliphatic-aryl; R1 and R2 independently denote unsubstituted -C1-8-aliphatic; -C1-8-aliphatic-C5-cycloaliphatic, -C1-8-aliphatic-aryl; n denotes 0; X denotes -NRa-; Ra denotes unsubstituted -C1-8-aliphatic; Rb denotes unsubstituted -C1-8-aliphatic; "aliphatic" represents a straight saturated hydrocarbon residue which is unsubstituted or mono- or multi-substituted with F atoms; "cycloaliphatic" represents a saturated, unsubstituted monocyclic hydrocarbon residue with 5 carbon atoms in the ring; "aryl" represents phenyl, which can be substituted with -F, -R0 and -OR0; "heteroaryl" represents a 5-member cyclic aromatic moiety containing 1 heteroatom. The heteroatom is N or S, and the heterocyclic ring can be substituted with -F, -R0 and -OR0; the heterocyclic ring can be part of a bicyclic system including phenyl.

EFFECT: invention also relates to a drug containing said compounds and use of the compounds to produce a drug for treating pain, stress, epilepsy, learning and memory disorders, drug dependence, cardiovascular diseases, eating disorders and locomotory impairments.

9 cl, 10 tbl, 164 ex

FIELD: chemistry.

SUBSTANCE: invention relates to sulphonamide compounds of formula or pharmaceutically acceptable salts thereof, wherein A is phenyl, optionally substituted with 1 or 2 halogen atoms, C1-6 alkyl group, trifluoromethyl group, C1-6 alkoxy group or -SCH3 group, thiophenyl, optionally substituted with a C1-C6 alkyl group or a halogen atom, pyridinyl, optionally substituted with a halogen atom, naphthalenyl or dihydroindenyl; R1 denotes the following formulae or [in formulae (R1a) and (R1b) Ar1 denotes the following formulae , or (each R5 and R6 independently denotes a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally substituted with up to three halogen atoms, C1-6 lower alkoxy group optionally substituted with up to three halogen atoms); Ar2 denotes the following formulae , or (each R7 and R8 independently denotes a hydrogen atom, a hydroxyl group, a halogen atom, a C1-6 alkyl group optionally substituted with up to three halogen atoms or a C1-6 lower alkoxy group optionally substituted with up to three halogen atoms, an amine group, a nitro group, a C2-6 acyl group, or R7 and R8 together form -CH2CH2O-; R9 is a hydrogen atom or - J-COOR10; J is a covalent bond, alkylene containing 1 to 5 carbon atoms, alkenylene containing 2 to 5 carbon atoms or alkynylene containing 2 to 5 carbon atoms, where one carbon atom in said alkylene groups can be substituted with an oxygen atom, a sulphur atom, NR11, CONR11 or NR11CO in any chemically acceptable position; R11 is a hydrogen atom; and R10 is a hydrogen atom); and p equals 0 or 1]; R2 is a C1-6 alkyl group; each R3 and R4 is independently a C1-6 alkyl group; * denotes an asymmetric carbon atom; and m equals an integer from 1 to 3. The invention also relates to a medicinal agent for stimulating PTH secretion.

EFFECT: obtaining novel compounds which can be used in medicine to prevent or treat primary or secondary osteoporosis.

29 cl, 15 tbl, 14 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel 4-trimethylammonio-butyrates of formula I

,

where A1, R1, m and n are as defined in the description and in the claim, as well as pharmaceutically acceptable salts thereof.

EFFECT: compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments for therapeutic or preventive treatment of hyperglycemia, glucose tolerance disorders, diabetes and associated pathologies, non-insulin dependent diabetes mellitus, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure.

13 cl, 1 tbl, 39 ex

Up!